Clinical tests were carried out in the representative group of patients with focal left-sided pneumonia (5 men and 7 women aged 18–41). Special-use product was included in in-patient department patients’ diet: 2 tablets in the first intake, then 1 tablet 4 times a day. Course of treatment was 21 days. Biologically active dietary supplement was prescribed together with general therapeutic treatment according to generally accepted standards of care. Control group included 15 patients randomized depending on sex and age who took only medicine. The author measured body temperature, studied the results of general blood tests, determined the level of C-reactive protein and seromucoids, performed R-graphy of lungs, electrocardiogram before and after treatment, analyzed clinical symptoms (cough, type of expectoration, shortness of breath). Composition of the special-use product was scientifically justified taking pharmacological characteristics of its ingredients and their active agents into account. Introduction of the biologically active dietary supplement in addition to the prescribed therapeutic treatment gave positive effect in relation to the inflammatory process: the patients could easier clear their throats from expectoration, coughed less frequently, and had less intense shortness of breath. It was evident that symptoms of disease recrudescence decreased. It appeared in the decreased intensity and length of fever. In case of acute respiratory viral infection the biologically active dietary supplement had antipyretic activity due to the anti-exudative effect of its ingredients. The author determined the anti-inflammatory effect and reduction of acute intoxication symptoms taking the results of general blood analysis into account. Patients who took special-use product had lower values of an inflammatory process marker – seromucoids. Tissues restored easily. The tested product has anti-inflammatory, antipyretic and analgesic properties. It can be used in complex treatment of acute inflammatory diseases and recrudescence of chronic inflammatory processes.

A new type of biologically active dietary supplement -BADS Hepar Formula was developed. The composition of BADS was justified, which proved to have synergistic properties forming a balanced complex for the maintenance of liver metabolic processes, protection and restoration of its cells in conditions of pathological changes. A possible mechanism of participation of functional ingredients of the developed product in relation to metabolic processes in liver diseases is presented. The purpose of the study is to carry out in situ tests of Hepar Formula among children with chronic viral hepatitis. Clinical evidence of functional properties of the new type of biologically active dietary supplement is provided. The therapeutic efficacy of the developed product is studied by including BADS in the diet of 20 children aged 9 to 14 years with chronic viral hepatitis B and C in the integration phase of the infectious process. Clinical symptoms were investigated in the dynamics of dietary therapy. By the end of the treatment, good and satisfactory results were reported in 90% of the children of the main group and 80 % of the control group. The developed product contributes to the improvement of adaptation capabilities of the child's body. Side effects in the application of BADS Hepar Formula are not noted, which is essential for pediatric practice. It is possible to combine the developed product with other drugs. The results of in situ tests showed that the inclusion of BADS into the baseline therapy contributes to reparative processes in liver cells, accelerates tissue regeneration after inflammatory diseases, improves the general condition, has hepatoprotective and anti-inflammatory effects. The new kind of hepatoprotector can be used in prevention and complex treatment of chronic liver diseases. The opinion of the Expert Council of the Russian Federation was received, the developed product is included into the Federal BADS Register.

No abstract